Genitourinary Cancers

This work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.

The FDA has granted a full approval to pembrolizumab for the treatment of platinum-ineligible patients with urothelial cancer.

“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.

Robert A. Figlin, MD, details how his institution, Cedars-Sinai Cancer, is aiming to fully understand the cancer journey for those with genitourinary malignancies.

Enfortumab vedotin-ejfv has been approved by the FDA for locally advanced or metastatic urothelial cancer.

Neal D. Shore, MD, FACS, discusses the importance of multidisciplinary care for patients with advanced prostate cancer.

Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting.

Petros Grivas, MD, PhD, discusses the impact of avelumab on patients with advanced urothelial carcinoma in the first-line maintenance setting.

Pembrolizumab plus gemcitabine and concurrent hypofractionated radiotherapy to treat patients with MIBC demonstrated safety and efficacy.

Based on results of the recently reported phase 3 CheckMate 274 trial, the FDA has granted priority review designation to nivolumab for the adjuvant treatment of high-risk muscle-invasive bladder cancer.

Accelerated approval for atezolizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for certain chemotherapy regimens was maintained by an FDA committee vote.

ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.

Based on results from the EV-301 and EV-201 trials, 2 separate applications for enfortumab vedotin as therapy for certain patients with previously treated metastatic urothelial carcinoma were accepted by the FDA and granted priority review.

Based on results of the phase 2 TROPHY-U-01 trial, the FDA has given accelerated approval to sacituzumab govitecan for previously treated, locally advanced or metastatic urothelial carcinoma.

Leonard G. Gomella, MD, FACS, detailed updated information regarding the standard of care and overall management of patients with non-muscle invasive bladder cancer at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

Scott G. Hubosky, MD, of Jefferson University Hospitals, discussed methods of treating patients with upper tract urothelial carcinoma at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

As part of an industry-wide assessment of indications based on accelerated approval, Roche in consultation with the FDA has decided to withdraw the indication for atezolizumab in patients with urothelial carcinoma following platinum-based chemotherapy.

Data published in The Lancet Oncology found that a hypofractionated radiation schedule of 55 Gy in 20 fractions is noninferior to a schedule of 64 Gy in 32 fractions for patients with this disease.

Continued approval for durvalumab in previously treated adult patients with locally advanced or metastatic bladder cancer was dependent upon results from the phase 3 DANUBE trial in the first-line metastatic bladder cancer setting, which did not meet its primary end points in 2020.

The biologics license application is for the locally administered fusion protein Vicineum for the treatment of high-risk, bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer.

In patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors, enfortumab vedotin induced the highest response rates seen with any regimen in this setting.

In non-muscle invasive bladder cancer carcinoma in-situ that is not responsive to BCG alone, the addition of N-803 leads to efficacy while maintaining safety.

Adjuvant therapy with nivolumab was superior to placebo for improving disease-free survival in patients with muscle-invasive urothelial carcinoma.

Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy.

Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed additional clinical evidence.

Avelumab plus best supportive care as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy.

High response rates with novel eganelisib plus PD-1 inhibition is reported in patients with metastatic urothelial carcinoma, especially those with low PD-L1 expression.

The procedure provided effective, long-term local control for patients with localized penile cancer, highlighting the need for a multidisciplinary approach to patient care.

The FDA  approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

Results of this phase III trial could change the current standard of care for treating nonseminomatous or combined germ cell tumors of the testis.